IL13 and Alzheimer disease: Unlike AD, where dupilumab monotherapy (a monoclonal antibody that blocks IL-4 and IL-13 signaling) significantly improves disease activity and reverses AD-associated epidermal abnormalities31, dupilumab primarily reduces the dosage of corticosteroids in BP32.